Motif Bio PLC has been dealt a serious blow from the US Food and Drug Administration which has told the cash-strapped UK biotech it needs to carry out an additional trial for iclaprim if it wants any hope of getting approval for the antibiotic.
The company has been on unsteady ground ever since February when the FDA issued a complete response letter for iclaprim,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?